Jonathan Dordick
Howard P Isermann Professor and Director, Rensselaer Polytechnic Institute (RPI), New York
Speaker
Jonathan Dordick received
his BA degree in Biochemistry and Chemistry from Brandeis University and his PhD
from the Massachusetts Institute of Technology in Biochemical Engineering. In
1987, Dr Dordick joined the Department of Chemical and Biochemical Engineering
at the University of Iowa. He was promoted to Associate Professor in 1991, to
Full Professor in 1994, and served as Department Chair from 1995–1998. He was
also Associate Director of the Center for Biocatalysis and Bioprocessing at the
University of Iowa and held a joint position in the Department of Medicinal and
Natural Products Chemistry in the College of Pharmacy. In 1998, Prof Dordick
joined the faculty at Rensselaer Polytechnic Institute as Chair of the
Department of Chemical Engineering where he is also the Howard P Isermann
Professor of Biochemical Engineering.
Professor Dordick’s current research includes
molecular bioprocessing (including high-throughput bioprocessing in drug and
functional materials discovery), biomaterials development, biocatalytic
nanocomposites, and protein structure and function in abiotic environments.
Professor Dordick received the NSF Presidential Young
Investigator Award in 1989, a University of Iowa Faculty Scholars Award, and
was elected as a Fellow of the American Institute of Medical and Biological
Engineers in 1996. He is highly active in the biotechnology community, serving
as Chair of the Division of Biochemical Technology of the ACS in 1992, and
presently he serves on the Scientific Advisory Boards for several biotechnology
companies. Dr Dordick is a co-founder of EnzyMed, Inc. a pharmaceutical and agrochemical
discovery company. Dr Dordick has published 118 papers and is an inventor or co-inventor
on 14 patents.
Presentation Summary
Adverse
drug reactions are a leading cause of death in the United States, deaths which
are preventable with a better understanding of how drugs interact with the
human body.
Rigorous
drug testing is required to ensure that drugs which may cause adverse reactions
are eliminated before they are made available. The final stage in drug testing
requirements remains the weak link, because drugs are tested on animals. Animal
reactions do not necessarily correlate with human reactions to the same
chemicals.
For
testing to truly predict how humans will react, the drug needs to be evaluated
on human cells. Biocatalysis and human cell culture offer the opportunity to
test activity and toxicity of drugs in an environment that mimics the human
body.
Biocatalysis
offers a more efficient and more robust testing environment, with reduced
testing cost, the development of better drugs and a reduced incidence of
adverse reactions among human recipients.